What is the definition of Maturity Onset Diabetes of the Young?

Maturity-onset diabetes of the young (MODY) is a form of diabetes that is characterized by an early onset diabetes.  MODY represents about 2% of all diabetes cases and is commonly misdiagnosed as type 1 or type 2 diabetes mellitus. It is due to a primary defect in pancreatic β-cell function. There are several MODY subtypes with distinct genetic causes: MODY1, caused by mutations in the HNF4A gene; MODY2, caused by mutations in GCK gene; MODY3 caused by mutations in the HNFA1 (the most common type); MODY4 caused by mutations in the PDX1 gene; MODY5 caused by mutations in the HNF1B gene; MODY6 caused by mutations in the NEUROD1 gene; MODY7 caused by mutations in the KLF11 gene; MODY8 caused by mutations in the CEL gene; MODY9 caused by mutations in the PAX4 gene; MODY10 caused by mutations in the INS gene; MODY11 caused by mutations in the BLK gene; MODY12 caused by mutations in the ABCC8 gene; MODY13  caused by heterozygous mutation in the KCNJ11 gene; and MODY14 caused by mutations in the APPL1 gene. It is inherited in an autosomal dominant pattern. Treatment depends on the subtype and may include sulfonylureas, insulin or diet and exercise.

What are the alternative names for Maturity Onset Diabetes of the Young?

  • MODY
  • Mason type diabetes
  • Condition: Type 2 Diabetes
  • Journal: Revue medicale suisse
  • Treatment Used: Sacubitril/Valsartan Combination
  • Number of Patients: 0
  • Published —
This article discusses the use of sacubitril/valsartan combination in the treatment of patients with type 2 diabetes.
  • Condition: Type 2 Diabetes
  • Journal: The New England journal of medicine
  • Treatment Used: Tirzepatide versus Semaglutide Once Weekly
  • Number of Patients: 1879
  • Published —
The study compared the outcomes between tirzepatide versus semaglutide once weekly for patients with type 2 diabetes.
Clinical Trial
  • Status: Not yet recruiting
  • Phase: N/A
  • Intervention Type: Behavioral
  • Participants: 1000
  • Start Date: May 2021
Empowering Patients With Chronic Disease Using Profiling and Targeted Feedbacks Delivered Through Wearable Device (EMPOWER)
Clinical Trial
  • Status: Recruiting
  • Phase: N/A
  • Intervention Type: Other
  • Participants: 200
  • Start Date: October 28, 2018
Personalized Nutrition for Diabetes Type 2